Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Kidney cancer: The Cytokine Working Group experience (1986-2001) - Part II: Management of IL-2 toxicity and studies with other cytokines
Autore:
Dutcher, J; Atkins, MB; Margolin, K; Weiss, G; Clark, J; Sosman, J; Logan, T; Aronson, F; Mier, J;
Indirizzi:
Our Lady Mercy New York Med Coll, Bronx, NY USA Our Lady Mercy New York Med Coll Bronx NY USA rk Med Coll, Bronx, NY USA
Titolo Testata:
MEDICAL ONCOLOGY
fascicolo: 3, volume: 18, anno: 2001,
pagine: 209 - 219
SICI:
1357-0560(2001)18:3<209:KCTCWG>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACTIVATED KILLER CELLS; IFN-GAMMA PRODUCTION; ANTITUMOR-ACTIVITY; MALIGNANT-MELANOMA; PLATELET-FUNCTION; INTERFERON-GAMMA; TUMOR-REGRESSION; PHASE-II; INTERLEUKIN-2; THERAPY;
Keywords:
kidney cancer; cytokines; renal cell cancer; treatment;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
43
Recensione:
Indirizzi per estratti:
Indirizzo: Dutcher, J Our Lady Mercy Med Ctr, Ctr Comprehens Canc, 600 E 233 St, Bronx, NY 10466USA Our Lady Mercy Med Ctr 600 E 233 St Bronx NY USA 10466 10466USA
Citazione:
J. Dutcher et al., "Kidney cancer: The Cytokine Working Group experience (1986-2001) - Part II: Management of IL-2 toxicity and studies with other cytokines", MED ONCOL, 18(3), 2001, pp. 209-219

Abstract

The Cytokine Working Group (CWG) was initially established in 1986 as the Extramural IL-2/LAK Working Group. With funding from the National Cancer Institute (NCI), the CWG was mandated to confirming data regarding the efficacy of the high-dose interleukin-2 (IL2)/lymphokine-activated killer cell (LAK cell) regimen piloted at the NCI in the treatment of renal cell cancer. Since those initial studies, the CWG has conducted a series of clinical trials, often with correlative immunologic investigations, to evaluate combination immunotherapy in attempts to enhance the efficacy of IL-2 or to reducetoxicity. Subsequently, the CWG conducted trials to demonstrate the activity of lower-dose outpatient combination cytokine regimens to help determinetheir role in the armamentarium of treatment for metastatic renal cell cancer. This has culminated in a phase III randomized trial comparing the activity of high-dose IL-2 with the activity of outpatient IL-2 plus interferon-ix. The CWG also has honed the management of both high-dose IL-2 and outpatient IL-2 regimens to make these safer in the hands of experienced clinicians. In addition, the CWG has produced a series of carefully conducted clinical trials of new cytokines, again attempting to define their clinical efficacy as anticancer agents. These include studies of IL-4, IL-6, and IL-12. Currently, the CWG is conducting studies with new approaches to IL-2 therapy, as well as planning trials with new agents for treatment of renal cell cancer. This review describes these efforts conducted over the past 15 yr.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/11/20 alle ore 21:02:00